• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Immatics N.V. (Amendment)

    2/10/23 4:01:15 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    SC 13G/A 1 ea173206-13ga2dievini_immat.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

    IMMATICS N.V.

    (Name of Issuer)

     

    Ordinary shares, nominal value €0.01 per share

    (Title of Class of Securities)

     

    N44445109

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)

     

      ☐ Rule 13d-1(c)

     

      ☒ Rule 13d-1(d)

     

      * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

     

     

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 2 of 15 Pages

     

    1.   

    Name of Reporting Persons

     

    dievini Hopp BioTech holding GmbH & Co. KG

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1) 

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    17,202,356 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    17,202,356 ordinary shares (2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    17,202,356 ordinary shares (2)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    26.2(3)

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 3 of 15 Pages

     

    1.   

    Name of Reporting Persons

     

    DH-LT-Investments GmbH

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1) 

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    726,282 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    726,282 ordinary shares (2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    726,282 ordinary shares (2)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

            

    1.1%(3)

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 4 of 15 Pages

     

    1.   

    Name of Reporting Persons

     

    DH-Capital GmbH & Co. KG

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1) 

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person

    With:

      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    17,202,356 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    17,202,356 ordinary shares (2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    17,202,356 ordinary shares common shares (2)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    26.2%(3)

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 5 of 15 Pages

     

    1.   

    Name of Reporting Persons

     

    OH Beteiligungen GmbH & Co. KG

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1) 

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    17,202,356 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    17,202,356 ordinary shares(2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    17,202,356 ordinary shares(2)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    26.2%(3)

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 6 of 15 Pages

     

    1.   

    Name of Reporting Persons

     

    Dietmar Hopp

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1) 

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    17,202,356 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    17,202,356 ordinary shares (2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    17,202,356 ordinary shares(2)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    26.2%(3)

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 7 of 15 Pages

     

    1.   

    Name of Reporting Persons

     

    Oliver Hopp

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1) 

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    17,202,356 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    17,202,356 ordinary shares (2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    17,202,356 ordinary shares(2)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    26.2%(3)

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 8 of 15 Pages

     

    1.  

    Name of Reporting Persons

     

    Daniel Hopp

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1)

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    17,202,356 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    17,202,356 ordinary shares (2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    17,202,356 ordinary shares (2)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    26.2%(3)

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents 14,901,384 shares held of record by dievini, 726.,82 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power,.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 9 of 15 Pages

     

    1.  

    Name of Reporting Persons

     

    Prof. Dr. Friedrich von Bohlen und Halbach

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1) 

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    627,524 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    627,524 ordinary shares (2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    627,524 ordinary shares (2)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    1.0%(5)

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents shares held by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, for which dievini has shared voting and dispositive power.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 10 of 15 Pages

     

    1.  

    Name of Reporting Persons

     

    Prof. Dr. Christof Hettich

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1) 

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    617,645 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    617,645 ordinary shares (2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    617,645 ordinary shares (2)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.9(3)

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents shares held by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, for which dievini has shared voting and dispositive power.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 11 of 15 Pages

     

    1.  

    Name of Reporting Persons

     

    Dr. Mathias Hothum

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ (1) 

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Germany

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person

    With:

      5.   

    Sole Voting Power

     

    0 ordinary shares

      6.  

    Shared Voting Power

     

    329,521 ordinary shares (2)

      7.  

    Sole Dispositive Power

     

    0 ordinary shares

      8.  

    Shared Dispositive Power

     

    329,521 ordinary shares (2)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    329,521 (2) ordinary shares

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.5(3)

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Represents shares held by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum for which dievini has shared voting and dispositive power.

     

    (3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 12 of 15 Pages

     

    Introductory Note: This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments, GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”) in respect of ordinary shares of Immatics N.V.

     

    Item 1(a) Name of Issuer:

     

    Immatics N.V.

     

    Item 1(b) Address of Issuer’s principal executive offices:

     

    Paul-Ehrlich-Straße 15

    72076 Tübingen, Germany

     

    Items 2(a) Name of Reporting Persons filing:

     

    dievini Hopp BioTech holding GmbH & Co. KG (“dievini”)

    DH-LT-Investments GmbH (“DH-LT-Investments”)

    DH-Capital GmbH & Co. KG (“DH-Capital”)

    OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”)

    Dietmar Hopp

    Oliver Hopp

    Daniel Hopp

    Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”)

    Prof. Dr. Christof Hettich (“Dr. Hettich”)

    Dr. Mathias Hothum (“Dr. Hothum”)

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    The address of the principal business office of dievini, DH-LT Investments, and Dietmar Hopp is c/o dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor Straße 57, 69190 Walldorf, Germany.

     

    The address of the principal business office of DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG is Heidelberger Straße 43, 69168 Wiesloch, Germany.

     

    The address of the principal business office of Oliver Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany.

     

    The address of the principal business office of Daniel Hopp is Johann-Jakob-Astor-Straße 57, 69190 Walldorf, Germany.

     

    The address of Dr. Hettich is Silcherstraße 6, 68723 Schwetzingen, Germany.

     

    The address of Dr Hothum is Bürgermeister-Willinger-Straße 3, 69190 Walldorf, Germany.

     

    The address of Dr von Bohlen is Neuenheimer Landstraße 4, 69120 Heidelberg, Germany.

     

    Item 2(c) Citizenship:

     

    Name   Citizenship or Place of Organization
    Dievini   Germany
    DH-Capital   Germany
    OH Beteiligungen   Germany
    Dietmar Hopp   Germany
    Oliver Hopp   Germany
    Daniel Hopp   Germany
    Dr. von Bohlen   Germany
    Dr. Hettich   Germany
    Dr. Hothum   Germany
    DH-LT Investments   Germany

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 13 of 15 Pages

     

    Item 2(d) Title of class of securities:

     

    Ordinary shares, nominal value €0.01 per share.

     

    Item 2(e) CUSIP No.:

     

    N44445109

     

    Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

     

    Not applicable.

     

    Item 4 Ownership

     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  

     

    DH-Capital and OH Beteiligungen are collectively the holders of 100% of the limited partner interest in dievini and therefore, control the voting and dispositive decisions of dievini together and may be deemed to beneficially own the shares held by dievini. Dietmar Hopp, Oliver Hopp and Daniel Hopp are the ultimate controlling persons of dievini, DH-Capital and OH Beteiligungen, and control the voting and investment decisions of the ultimate parent company of dievini and therefore, may be deemed to beneficially own the shares held by dievini by virtue of their status as controlling persons of dievini.

     

    Item 5 Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ☐

     

    Item 6 Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8 Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9 Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10 Certifications

     

    Not applicable.

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 14 of 15 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 10, 2023

     

      DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG
         
      By: dievini Verwaltungs GmbH
        its General Partner
         
      By: /s/ Dr. Marc Hauser
        Name: Dr. Marc Hauser
        Title: Attorney-in-fact
       
      DH-CAPITAL GMBH & CO. KG
         
      By: DH Verwaltungs GmbH
        its General Partner
         
      By: /s/ Dr. Marc Hauser
        Name: Dr. Marc Hauser
        Title: Attorney-in-fact
       
      OH BETEILIGUNGEN GMBH & CO. KG
         
      By: OH Verwaltungs GmbH
        its General Partner
         
      By: /s/ Dr. Marc Hauser
        Name:  Dr. Marc Hauser
        Title: Attorney-in-fact

     

      /s/ Dr. Marc Hauser as attorney-in-fact
      DIETMAR HOPP
       
      /s/ Dr. Marc Hauser as attorney-in-fact
      OLIVER HOPP
       
      /s/ Dr. Marc Hauser as attorney-in-fact
      DANIEL HOPP
       
      /s/ Dr. Marc Hauser as attorney-in-fact
      FRIEDRICH VON BOHLEN UND HALBACH
       
      /s/ Dr. Marc Hauser as attorney-in-fact
      CHRISTOF HETTICH
       
      /s/ Dr. Marc Hauser as attorney-in-fact
      MATHIAS HOTHUM

     

      DH-LT INVESTMENTS GMBH
         
      By: /s/ Dr. Marc Hauser
      Name:  Dr. Marc Hauser
      Title: Attorney-in-fact

     

     

     

     

    CUSIP NO. N44445109   13 G   Page 15 of 15 Pages

     

    Exhibit(s):

     

    1 – Power of Attorney: Incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons on February 12, 2021 with respect to the common shares of the Issuer.
       
    2 – Joint Filing Statement: Incorporated by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on February 12, 2021 with respect to the common shares of the Issuer.

     

     

     

     

    Get the next $IMTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    9/18/2025$16.00Buy
    Guggenheim
    5/28/2025$10.00Buy
    Deutsche Bank
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings

    $IMTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

    IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced solid tumors after one-time infusion of IMA203CD8 at a low median dose during ongoing dose escalation, including deep and durable responses Promising dose-dependent clinical signal in ovarian carcinoma supports the strategy to position IMA203CD8 in the tumor-agnostic setting of advanced PRAME cancers beyond melanoma, starting with gynecologic cancersDose escalation and determination of RP2D on track to be completed in 2026, including data on two highest dose levels Houston, T

    12/11/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces $125 Million Underwritten Offering

    Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary closing conditions.   Jefferies, Leerink Partners and Cantor are acting as joint book-running managers for the offering. A registration statement rela

    12/5/25 6:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces Third Quarter 2025 Financial Results and Business Update

    Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at 14.3 months mFUIMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial ongoing with next data update, including dose escalation data in ovarian cancer

    11/17/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Immatics N.V. with a new price target

    Guggenheim initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $16.00

    9/18/25 8:43:36 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Deutsche Bank initiated coverage on Immatics N.V. with a new price target

    Deutsche Bank initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $10.00

    5/28/25 9:08:28 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Immatics N.V. with a new price target

    Piper Sandler initiated coverage of Immatics N.V. with a rating of Overweight and set a new price target of $19.00

    10/7/24 7:57:11 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    SEC Filings

    View All

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    1/12/26 4:09:23 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    12/11/25 7:10:17 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    12/8/25 4:20:54 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Leadership Updates

    Live Leadership Updates

    View All

    Immatics Announces Third Quarter 2025 Financial Results and Business Update

    Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at 14.3 months mFUIMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial ongoing with next data update, including dose escalation data in ovarian cancer

    11/17/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Appoints Amie Krause as Chief People Officer

    Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer ("CPO") effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across global biopharmaceutical companies. In this newly established role, she will lead Immatics' human resources, focusing on organizational development and operations as the company transitions to commercial stage."As we

    10/27/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Appoints Venkat Ramanan as Chief Financial Officer

    Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer ("CFO"), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos The

    10/1/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Financials

    Live finance-specific insights

    View All

    Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

    Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME Bispecific at RP2D range resulted in a 30% cORR (6/20) across all indications, including 29% (4/14) in melanoma and 2/3 confirmed responses in ovarian carcinoma IMA401 MAGEA4/8 Bispecific at ≥1 mg resulted in a 25% cORR (2/8) in head and neck cancer, 29% cORR (2/7) in melanoma and promising clinical activity in sqNSCLC Phase 1a dose escalation completed for both trials; data support IMA402 PRAME Bispecific dev

    11/12/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

    Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial Regulatory pathway and clinical trial design for IMA203 finalized following FDA Type D meetings and meeting with the Paul Ehrlich Institute (PEI); RP2D and CMC package confirmedIMA203 conti

    10/10/24 6:30:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

    Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today, November 8 IMA203 GEN1 TCR cell therapy targeting PRAME – update on Phase 1a and Cohort A Continues to be well tolerated50% confirmed objective response rate (cORR) in melanoma patients treated at recommended Phase 2 dose; durability with some ongoing responses at >15 months and median duration of response not reached at a median follow-up of 14.4 monthsTargeted to enter registration-enabling Phase 2 trial in melanoma in 2024; discussions with FDA ongoing based on recently ob

    11/8/23 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Immatics N.V.

    SC 13G - Immatics N.V. (0001809196) (Subject)

    11/14/24 1:28:33 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Immatics N.V.

    SC 13G - Immatics N.V. (0001809196) (Subject)

    11/14/24 6:32:45 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immatics N.V.

    SC 13G/A - Immatics N.V. (0001809196) (Subject)

    11/8/24 10:46:38 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care